Results 101 to 110 of about 3,955 (172)

Therapeutic potential of cytokine-induced killer cell therapy for renal cell carcinoma and prostate cancer. [PDF]

Cell Commun Signal
Lee IT, Wang YL, Hong JH, Huang CY, Vo TTT, Lee WJ, Chiang CH.   +6 more
europepmc   +1 more source

Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges. [PDF]

Cancer Immunol Immunother
Luo Q, Jiang W, Xie Y, Dai Z, Zhu J, Du Y, Tao X, Lei Z, Chu X, Wang B, Fu G.   +10 more
europepmc   +1 more source

Efficacy of modified dendritic cell-cytokine-induced killer cells loaded with tumour stem cell membrane microparticle therapy in the treatment of relapsed or refractory T- and NK-cell lymphoid proliferations and lymphomas: a report of three cases. [PDF]

Ann Hematol
Wang A, Fan T, Zhang J, Ye M, Huang H, Gao ZL.   +5 more
europepmc   +1 more source

Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial. [PDF]

Cancer Immunol Immunother
Shin H, Park Y, Song BG, Choi WM, Han HJ, Lee Y, Song TJ, Yeon JE, Lim YS, Hur MH, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee JH, Yoon JH, Lee JH.   +16 more
europepmc   +1 more source

Therapeutic Potential of CAR-CIK Cells in Acute Leukemia Relapsed Post Allogeneic Stem Cell Transplantation. [PDF]

Cancers (Basel)
Canichella M, de Fabritiis P, Abruzzese E.   +2 more
europepmc   +1 more source

Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma. [PDF]

Sci Rep
Li S, Qin J, Sun Q, Zhao H, Xiong Y, Wang Y, Han Y, Zhang J, Zhang W, Shen M, Yang F, Ren B, Zhou L, Li R, Hui Z, Tian X, Cao S, Du W, Yu W, Liu L, Zhang X, Ren X.   +21 more
europepmc   +1 more source

From bench to bedside: advances in cell therapy for tuberculosis treatment. [PDF]

Stem Cell Res Ther
Chunxiao L, Junsheng F, Xuerong C, Xiaomin W, Shuihua L.   +4 more
europepmc   +1 more source

Synergistic antitumor efficacy of CIK cells combined with PD-1 inhibitors in nasopharyngeal carcinoma. [PDF]

Am J Transl Res
Chen J, Sailihan T, Chen Y, Xv S, Qian J, Shen X, Yang H, Zhang P.   +7 more
europepmc   +1 more source

CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy. [PDF]

Front Oncol
Chen P, Pan J, Chen L, Feng X.
europepmc   +1 more source

Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer. [PDF]

Front Immunol
Zhu Y, Xiong G, Guan M, Sun D, Guo Y, Peng J, Zhu H.   +6 more
europepmc   +1 more source